TARS (Tarsus Pharmaceuticals) 6-Month Price Index: 1.14 (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TARS Tarsus Pharmaceuticals Inc TARS
44 GF Score
Price $69.24
GF Value $156.61
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Tarsus Pharmaceuticals 6-Month Price Index?

Tarsus Pharmaceuticals TARS +0.52% 44 6-Month Price Index is 1.14 as of Aug. 17, 2026. GuruFocus rates TARS with a GF Score™ of 44/100 and a GF Value™ of $156.61 (Significantly Undervalued). The stock has 1 warning sign investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-17), Tarsus Pharmaceuticals's 6-Month Price Index is 1.14.

Tarsus Pharmaceuticals  (NAS:TARS) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Tarsus Pharmaceuticals 6-Month Price Index Related Terms

TARS vs VERA, BEAM, KOD: 6-Month Price Index Comparison

For the Biotechnology subindustry, Tarsus Pharmaceuticals's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TARS
44GF Score
Tarsus Pharmaceuticals Inc TARS
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tarsus Pharmaceuticals  (NAS:TARS) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.14 mean?
Tarsus Pharmaceuticals (TARS) has a 6-Month Price Index of 1.14 as of Aug. 17, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Tarsus Pharmaceuticals and its competitors.
Is Tarsus Pharmaceuticals' 6-Month Price Index too high?
Tarsus Pharmaceuticals' current 6-Month Price Index is 1.14. Overall, Tarsus Pharmaceuticals has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' 6-Month Price Index compare to VERA and BEAM?
Tarsus Pharmaceuticals' 6-Month Price Index of 1.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Tarsus Pharmaceuticals and its competitors. Tarsus Pharmaceuticals's current 6-Month Price Index is 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Significantly Undervalued. The stock's GF Value™ is $156.61, compared to a current price of $69.24 — trading 55.8% below its estimated fair value. The current 6-Month Price Index is 1.14. Tarsus Pharmaceuticals' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current 6-Month Price Index is 1.14 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $69.24 is trading 55.8% below its estimated GF Value™ of $156.61. GuruFocus considers Tarsus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for TARS:

  • 6-Month Price Index: 1.14
  • GF Value™: $156.61 vs. price of $69.24 (55.8% below fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
44GF Score

Get the complete analysis for TARS

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$69.24
Price
$156.61
GF Value